Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme

Peregrine Pharmaceuticals Announces $5.75 Million Investment From Institutional Investors; Company Director Invests in Offering

Peregrine Announces Image Fusion Data From Phase II Cotara Trial; Data To Be Presented at the Meeting of the World Federation of Neuro-Oncology